ERAS
Price
$1.57
Change
+$0.04 (+2.61%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
444.76M
63 days until earnings call
KALV
Price
$13.80
Change
+$0.26 (+1.92%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
686.32M
28 days until earnings call
Interact to see
Advertisement

ERAS vs KALV

Header iconERAS vs KALV Comparison
Open Charts ERAS vs KALVBanner chart's image
Erasca
Price$1.57
Change+$0.04 (+2.61%)
Volume$35.44K
Capitalization444.76M
KalVista Pharmaceuticals
Price$13.80
Change+$0.26 (+1.92%)
Volume$7.42K
Capitalization686.32M
ERAS vs KALV Comparison Chart
Loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KALV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERAS vs. KALV commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Buy and KALV is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (ERAS: $1.53 vs. KALV: $13.54)
Brand notoriety: ERAS and KALV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 119% vs. KALV: 87%
Market capitalization -- ERAS: $444.76M vs. KALV: $673.15M
ERAS [@Biotechnology] is valued at $444.76M. KALV’s [@Biotechnology] market capitalization is $673.15M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileKALV’s FA Score has 0 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • KALV’s FA Score: 0 green, 5 red.
According to our system of comparison, both ERAS and KALV are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 6 TA indicator(s) are bullish while KALV’s TA Score has 5 bullish TA indicator(s).

  • ERAS’s TA Score: 6 bullish, 4 bearish.
  • KALV’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than KALV.

Price Growth

ERAS (@Biotechnology) experienced а +41.67% price change this week, while KALV (@Biotechnology) price change was +20.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +9.95%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

ERAS is expected to report earnings on Aug 07, 2025.

KALV is expected to report earnings on Sep 04, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KALV($686M) has a higher market cap than ERAS($445M). KALV YTD gains are higher at: 59.858 vs. ERAS (-39.044). ERAS has higher annual earnings (EBITDA): -151.33M vs. KALV (-173.23M). ERAS has more cash in the bank: 319M vs. KALV (253M). KALV has less debt than ERAS: KALV (5.78M) vs ERAS (52.9M). ERAS (0) and KALV (0) have equivalent revenues.
ERASKALVERAS / KALV
Capitalization445M686M65%
EBITDA-151.33M-173.23M87%
Gain YTD-39.04459.858-65%
P/E RatioN/AN/A-
Revenue00-
Total Cash319M253M126%
Total Debt52.9M5.78M915%
FUNDAMENTALS RATINGS
KALV: Fundamental Ratings
KALV
OUTLOOK RATING
1..100
9
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
PROFIT vs RISK RATING
1..100
88
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
43
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ERASKALV
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 15 days ago
88%
Bearish Trend 10 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KALV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RGECX10.230.02
+0.20%
Russell Inv Global Equity C
FASMX21.15N/A
N/A
Fidelity Asset Manager 50%
IMORX17.26N/A
N/A
Voya MidCap Opportunities R
MECAX47.28N/A
N/A
AMG GW&K International Small Cap N
TRZIX14.84N/A
N/A
T. Rowe Price Small-Cap Index Z

KALV and

Correlation & Price change

A.I.dvisor indicates that over the last year, KALV has been loosely correlated with ATXS. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if KALV jumps, then ATXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KALV
1D Price
Change %
KALV100%
+1.42%
ATXS - KALV
47%
Loosely correlated
+6.45%
IDYA - KALV
47%
Loosely correlated
-2.50%
TRDA - KALV
45%
Loosely correlated
-3.76%
CRSP - KALV
45%
Loosely correlated
+0.03%
KYMR - KALV
45%
Loosely correlated
+1.56%
More